Preclinical studies using lipid nanoparticle (LNP)-encapsulated siRNA against hsa_circ_0136666, combined with anti-PD-L1 therapy, demonstrated synergistic tumor suppression, offering a potential strategy to overcome resistance to immune checkpoint inhibitors (109). The gene discussed is CD274; the disease is neoplasm.